A Weight-Loss Drug for Compulsive Hair-Pulling? Here's the Logic.

TL;DR: University of Chicago researchers are running a small open-label Phase 2 trial (NCT07282769, 10 participants) testing once-weekly semaglutide for trichotillomania, compulsive hair-pulling. The logic is neurobiological: GLP-1 receptors sit in the brain’s reward and impulse-control circuits, and trichotillomania is a disorder of those circuits. It is tiny, early, and hypothesis-generating. But the disorder has almost no good drug options, so even a signal would matter.

Trichotillomania affects an estimated 1 to 2 percent of people, and most have never heard the name. It is compulsive hair-pulling, often from the scalp, eyebrows, or eyelashes, and it is classified on the obsessive-compulsive spectrum.

It does real harm: scarring, infection, social distress, sometimes major hair loss. And it is badly understudied. The gold-standard treatment is a specific form of cognitive behavioral therapy called habit reversal training. Drug options are thin, mostly off-label, mostly modest.

Now University of Chicago researchers are testing a candidate nobody would have guessed: semaglutide.

The study, NCT07282769, is “Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study,” 10 participants, set to start in May 2026.

It is open-label, meaning everyone gets semaglutide and knows it, with no placebo arm. That is appropriate for early exploration. This is not a gold-standard randomized trial, and at this stage it does not need to be. If there is a signal, that justifies bigger, controlled work.

The logic runs through the brain, not the waistline.

Trichotillomania, like other compulsive behaviors, involves dysregulation in reward pathways and impulse-control circuits, particularly the orbitofrontal cortex and anterior cingulate cortex, the regions that drive repetitive behavior and put the brakes on impulses.

GLP-1 receptors are expressed throughout the brain, including those reward and behavioral-regulation regions. The hypothesis is that GLP-1 drugs may turn down the salience and urgency of a compulsive urge while strengthening impulse control. If semaglutide can make the pull less insistent, it offers something patients do not currently have: a drug aimed at the mechanism rather than the symptom.

This trial is part of a much bigger push. Researchers are testing GLP-1s for substance use disorders, binge eating, and now compulsive behaviors like this one, all on the same premise that these receptors regulate reward and impulse control. It is a reminder that the class is still being discovered while the headlines stay fixed on weight loss. What starts as a metabolic drug can become a behavioral-medicine tool, if the biology holds.

Plenty of this exploration will not pan out. That is how early research works. But the sheer number of trials launching across mental health and compulsive disorders tells you researchers think the GLP-1 mechanism reaches well past metabolism.

The open-label design and tiny enrollment mean this is hypothesis-generating. With no control group, any apparent benefit could be placebo, expectancy, or normal symptom fluctuation. The real questions: does semaglutide cut the frequency or intensity of pulling urges, do patients report better impulse control, and are there safety concerns giving this drug to a psychiatric population it was not built for.

Results are likely months out, maybe a year or more. If efficacy shows up, the next step is a larger, blinded, randomized trial. That is the line between early hope and clinical reality, and this trial is firmly on the early side of it.

APA Citation: University of Chicago. (2026). Once weekly semaglutide treatment of trichotillomania: An open-label study (NCT07282769). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07282769